SCHEMBL25300063

SCHEMBL25300063

OC[C@@H](O)COCCOCCOCCOCCOCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.57
CA2 P00918 2/20 0.57
CA7 P43166 2/20 0.57
CA9 Q16790 2/20 0.57
TSHR P16473 2/20 0.47
MAPK1 P28482 1/20 0.47
NAAA Q02083 1/20 0.45
CA4 P22748 1/20 0.44
CYP1A2 P05177 2/20 0.44
AGTR1 P30556 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.43
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
AGER Q15109 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24207966 1.00 CA1 (0.57) CA1CA2CA7CA9TSHR
SCHEMBL30590458 1.00 CA1 (0.57) CA1CA2CA7CA9TSHR
SCHEMBL3541327 0.91 CA1 (0.62) CA1CA2CA7CA9TSHR
SCHEMBL16269805 0.89 CA1 (0.70) CA1CA2CA7CA9TSHR
SCHEMBL508126 0.89 CA1 (0.70) CA1CA2CA7CA9TSHR
SCHEMBL218661 0.89 CA1 (0.70) CA1CA2CA7CA9TSHR
SCHEMBL122306 0.89 CA1 (0.70) CA1CA2CA7CA9TSHR
SCHEMBL3545404 0.89 CA1 (0.65) CA1CA2CA7CA9TSHR
SCHEMBL8270216 0.88 CA1 (0.56) CA1CA2CA7CA9TSHR
SCHEMBL25435936 0.86 CA1 (0.49) CA1CA2CA7CA9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114305-A1 LIPIDIC COMPOUNDS, AND USES THEREOF SANOFI (FR) 2025-04-10 US disclosed
EP-4466248-A1 LIPIDIC COMPOUNDS, AND USES THEREOF Sanofi (FR) 2024-11-27 EP disclosed
CN-118829624-A Lipid compound and use thereof 赛诺菲 2024-10-22 CN disclosed
WO-2023135305-A1 LIPIDIC COMPOUNDS, AND USES THEREOF SANOFI (FR) 2023-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250114305-A1 LIPIDIC COMPOUNDS, AND USES THEREOF NR1H2, NR1H3, LPAR3 CA1 2990/4885CA2 2496/4885CA7 2168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.